1. Home
  2. CLBK vs MESO Comparison

CLBK vs MESO Comparison

Compare CLBK & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLBK
  • MESO
  • Stock Information
  • Founded
  • CLBK 1927
  • MESO 2004
  • Country
  • CLBK United States
  • MESO Australia
  • Employees
  • CLBK N/A
  • MESO N/A
  • Industry
  • CLBK Savings Institutions
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CLBK Finance
  • MESO Health Care
  • Exchange
  • CLBK Nasdaq
  • MESO Nasdaq
  • Market Cap
  • CLBK 1.5B
  • MESO 1.2B
  • IPO Year
  • CLBK N/A
  • MESO N/A
  • Fundamental
  • Price
  • CLBK $16.68
  • MESO $13.31
  • Analyst Decision
  • CLBK Hold
  • MESO Strong Buy
  • Analyst Count
  • CLBK 1
  • MESO 4
  • Target Price
  • CLBK $17.00
  • MESO $11.50
  • AVG Volume (30 Days)
  • CLBK 61.8K
  • MESO 238.9K
  • Earning Date
  • CLBK 01-23-2025
  • MESO 08-28-2024
  • Dividend Yield
  • CLBK N/A
  • MESO N/A
  • EPS Growth
  • CLBK N/A
  • MESO N/A
  • EPS
  • CLBK 0.15
  • MESO N/A
  • Revenue
  • CLBK $201,023,000.00
  • MESO $5,902,000.00
  • Revenue This Year
  • CLBK N/A
  • MESO $66.05
  • Revenue Next Year
  • CLBK $19.06
  • MESO $348.27
  • P/E Ratio
  • CLBK $111.33
  • MESO N/A
  • Revenue Growth
  • CLBK N/A
  • MESO N/A
  • 52 Week Low
  • CLBK $13.79
  • MESO $1.61
  • 52 Week High
  • CLBK $20.46
  • MESO $12.70
  • Technical
  • Relative Strength Index (RSI)
  • CLBK 39.04
  • MESO 67.62
  • Support Level
  • CLBK $16.62
  • MESO $10.30
  • Resistance Level
  • CLBK $17.15
  • MESO $11.59
  • Average True Range (ATR)
  • CLBK 0.38
  • MESO 0.50
  • MACD
  • CLBK -0.14
  • MESO 0.10
  • Stochastic Oscillator
  • CLBK 12.71
  • MESO 77.98

About CLBK Columbia Financial Inc.

Columbia Financial Inc is a federally chartered savings bank that serves the financial needs of depositors and the local community as a community-minded, customer service-focused institution. It offers traditional financial services to businesses and consumers. It attracts deposits from the general public and uses those funds to originate a variety of loans, including multifamily and commercial real estate loans, commercial business loans, one-to-four family real estate loans, construction loans, home equity loans and advances, and other consumer loans, and also offers a broad range of insurance products, investment solutions, and wealth management services.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: